I
7.16
-0.34 (-4.53%)
| 前收盘价格 | 7.50 |
| 收盘价格 | 7.48 |
| 成交量 | 66,466 |
| 平均成交量 (3个月) | 70,295 |
| 市值 | 205,237,360 |
| 价格/销量 (P/S) | 40.44 |
| 股市价格/股市净资产 (P/B) | 87.06 |
| 52周波幅 | |
| 利润日期 | 10 Nov 2025 |
| 营业利益率 (TTM) | -273.01% |
| 稀释每股收益 (EPS TTM) | -3.79 |
| 季度收入增长率 (YOY) | 1,114.80% |
| 总债务/股东权益 (D/E MRQ) | 34.04% |
| 流动比率 (MRQ) | 3.74 |
| 营业现金流 (OCF TTM) | -22.74 M |
| 杠杆自由现金流 (LFCF TTM) | -15.27 M |
| 资产报酬率 (ROA TTM) | -22.17% |
| 股东权益报酬率 (ROE TTM) | -428.96% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看涨 | 看涨 |
| Diagnostics & Research (全球的) | 看涨 | 看涨 | |
| 股票 | Insight Molecular Diagnostics I | 看涨 | - |
AIStockmoo 评分
-0.6
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.63 |
|
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company’s flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 22.47% |
| 机构持股比例 | 56.26% |
| 52周波幅 | ||
| 中 | 9.00 (25.70%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 11 Nov 2025 | 9.00 (25.70%) | 购买 | 7.53 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合